American International Group, Inc. Olema Pharmaceuticals, Inc. Transaction History

American International Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$10.95 - $16.62 $1,248 - $1,894	-114 Reduced 0.85%	13,231 $149,000
Q4 2023 Feb 13, 2024	SELL	$10.53 - $17.14 $568 - $925	-54 Reduced 0.4%	13,345 $187,000
Q3 2023 Nov 13, 2023	BUY	$8.19 - $12.98 $3,906 - $6,191	477 Added 3.69%	13,399 $165,000
Q2 2023 Aug 04, 2023	BUY	$3.22 - $9.65 $41,608 - $124,697	12,922 New	12,922 $116,000
Q2 2022 Aug 12, 2022	SELL	$2.04 - $4.61 $25,987 - $58,726	-12,739 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.89 - $9.43 $2,524 - $6,120	-649 Reduced 4.85%	12,739 $54,000
Q4 2021 Feb 11, 2022	SELL	$8.75 - $30.71 $3,517 - $12,345	-402 Reduced 2.92%	13,388 $125,000
Q3 2021 Nov 12, 2021	BUY	$22.96 - $30.13 $160,582 - $210,729	6,994 Added 102.91%	13,790 $380,000
Q2 2021 Aug 13, 2021	SELL	$21.15 - $36.14 $5,795 - $9,902	-274 Reduced 3.88%	6,796 $190,000
Q1 2021 May 07, 2021	BUY	$27.81 - $53.64 $196,616 - $379,234	7,070 New	7,070 $235,000

136

58.7M

141K

23.1K

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $247M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.